Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011008931 - ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS

Publication Number WO/2011/008931
Publication Date 20.01.2011
International Application No. PCT/US2010/042103
International Filing Date 15.07.2010
IPC
A01N 43/54 2006.01
AHUMAN NECESSITIES
01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
43Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
48having rings with two nitrogen atoms as the only ring hetero atoms
541,3-Diazines; Hydrogenated 1,3-diazines
A61K 31/505 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
CPC
A61K 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
A61K 31/427
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
425Thiazoles
427not condensed and containing further heterocyclic rings
A61K 31/443
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
44Non condensed pyridines; Hydrogenated derivatives thereof
4427containing further heterocyclic ring systems
443containing a five-membered ring with oxygen as a ring hetero atom
A61K 31/506
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two ; or more; nitrogen atoms as the only ring heteroatoms, e.g. piperazine ; or tetrazines
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
506not condensed and containing further heterocyclic rings
A61K 31/538
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
535having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
53751,4-Oxazines, e.g. morpholine
538ortho- or peri-condensed with carbocyclic ring systems
Applicants
  • CYSTIC FIBROSIS FOUNDATION THERAPEUTICS, INC. [US]/[US] (AllExceptUS)
  • CHIANG, Phoebe [US]/[US] (UsOnly)
  • MENSE, Martin [US]/[DE] (UsOnly)
Inventors
  • CHIANG, Phoebe
  • MENSE, Martin
Agents
  • DAVIS, Chad E.
Priority Data
61/225,90615.07.2009US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ARYLPYRIMIDINE COMPOUNDS AND COMBINATION THERAPY COMPRISING SAME FOR TREATING CYSTIC FIBROSIS & RELATED DISORDERS
(FR) COMPOSÉS ARYLPYRIMIDINES ET THÉRAPIE DE COMBINAISON COMPRENANT CEUX-CI POUR TRAITER UNE MUCOVISCIDOSE ET DES TROUBLES APPARENTÉS
Abstract
(EN)
Provided herein are pharmaceutical compositions comprising an arylpyrimidine compound that modulates the activity of cystic fibrosis transmembrane regulator (CFTR) protein and a second compound that modulates the activity of a CFTR protein. Also provided are methods of treating a disorder associated with CFTR protein function by administering an arylpyrimidine compound that modulates the activity of a CFTR protein and a second compound that modulates the activity of a CFTR protein. The combination therapy can be used to treat, for example, airway inflammation and cystic fibrosis.
(FR)
L'invention porte sur des compositions pharmaceutiques comprenant un composé arylpyrimidine qui module l'activité d'une protéine régulatrice transmembranaire de la mucoviscidose (CFTR) et un second composé qui module l'activité d'une protéine CFTR. L'invention porte également sur des procédés de traitement d'un trouble associé à une fonction protéine CFTR par l'administration d'un composé arylpyrimidine qui module l'activité d'une protéine CFTR et un second composé qui module l'activité d'une protéine CFTR. La thérapie de combinaison peut être utilisée pour traiter, par exemple, une inflammation des voies aériennes et une mucoviscidose.
Latest bibliographic data on file with the International Bureau